Male Breast Cancer

Postoperatively, he received adjuvant stereotactic radiosurgery (30-35 Gy in five fractions) to the resection cavity and was transitioned from tamoxifen to trastuzumab deruxtecan (T-DXd) for improved CNS-directed systemic therapy. Surveillance imaging at 6 months demonstrated no intracranial recurrence, and systemic restaging showed no extracranial disease progression. This case highlights the importance of prompt neuroimaging for new neurological symptoms in male breast cancer patients and supports a multimodal strategy, including surgical resection, focal radiation, and CNS-penetrant HER2-targeted therapy, for achieving durable intracranial control in select patients with isolated brain metastasis.

Striking a balance between tumor control and risk-benefit ratio within a multidisciplinary team framework was essential. A tailored approach based on endocrine and palliative medications should be adopted to improve quality of life and short-term prognosis.

PMRT was associated with improved OS in selected MBC patients with high-risk features such as larger tumors or PR-negative disease. The consistent findings from SEER and SJTUBCDB support the use of PMRT in high-risk MBC patients and highlight the need for personalized treatment strategies and prospective trials.

Based on these results, TAM administration in healthy rats was associated with increased penile oxidative stress, while O3FA attenuated some of these changes.

RS as determined by the Oncotype DX assay is associated with OS in men and women with HR+ Her2- LN+ BC. However, RS is not an indicator of the benefit of chemotherapy on OS in men, in contrast to women, with HR+ Her2- LN+ BC.

Given the rarity of this tumor in males, accurate histopathological and immunohistochemical diagnoses are critical to avoid misclassification. Although the overall prognosis is favorable, close follow-up is warranted because of the potential for recurrence and metastases.

Our study enhances the understanding of MBC and provides valuable insights into clinical diagnosis and therapy.

Genetic predisposition plays an important role among young women and men in the study setting, with nearly one in four patients carrying a PV. The results call for further research and interventions targeting individuals at high risk, with the long-term potential of reduced morbidity and mortality.

P=N/A, N=200, Active, not recruiting, European Organisation for Research and Treatment of Cancer - EORTC | Trial completion date: Mar 2024 --> Dec 2026 | Trial primary completion date: Mar 2024 --> Dec 2026

RS testing increased between 2010 and 2023 for both sexes, and RS influenced receipt of chemotherapy. Male patients had higher RS but were less likely to receive chemotherapy when RS ≥ 26, and when chemotherapy was omitted, they had worse OS, revealing the importance of chemotherapy among males with high RS.

The use of artificial intelligence (AI) and machine learning are emerging options that have the potential to improve detectability and personalized treatment in both genders. The current review draws similarities between breast cancer in males and females to promote gender-specific interventions and better outcomes.